CN102895224A - Application of Aphanamixoid A in drugs for treating breast cancer - Google Patents
Application of Aphanamixoid A in drugs for treating breast cancer Download PDFInfo
- Publication number
- CN102895224A CN102895224A CN201210414597.5A CN201210414597A CN102895224A CN 102895224 A CN102895224 A CN 102895224A CN 201210414597 A CN201210414597 A CN 201210414597A CN 102895224 A CN102895224 A CN 102895224A
- Authority
- CN
- China
- Prior art keywords
- aphanamixoid
- breast cancer
- drugs
- application
- mcf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229930193702 aphanamixoid Natural products 0.000 title claims abstract description 26
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 25
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 title claims abstract description 16
- 229940079593 drug Drugs 0.000 title claims abstract description 16
- 230000012010 growth Effects 0.000 abstract description 7
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 230000000259 anti-tumor effect Effects 0.000 abstract description 2
- 238000011161 development Methods 0.000 abstract description 2
- 238000011156 evaluation Methods 0.000 abstract description 2
- OAVCWZUKQIEFGG-UHFFFAOYSA-O 2-(5-methyl-2H-tetrazol-1-ium-1-yl)-1,3-thiazole Chemical compound CC1=NN=N[NH+]1C1=NC=CS1 OAVCWZUKQIEFGG-UHFFFAOYSA-O 0.000 abstract 1
- 239000003560 cancer drug Substances 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 9
- 240000003906 Aphanamixis grandifolia Species 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 150000002630 limonoids Chemical class 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001887 anti-feedant effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses an application of Aphanamixoid A in preparing drugs for treating breast cancer and belongs to the technical field of new uses of the drugs. Discovered by in vitro methyl thiazolyl tetrazolium (MTT) antitumor activity evaluation, the Aphanamixoid A disclosed by the invention is also remarkable in inhibitory effect on the growth of human breast cancer cell lines 4T1, MCF-7, MDA-MB-231 and MCF-7B. Therefore, the Aphanamixoid A can be used for preparing anti-breast cancer drugs, and is good in development and application prospect. The application of the Aphanamixoid A in preparing the drugs for treating the breast cancer is disclosed for the first time. Moreover, the skeleton type of the Aphanamixoid A is fire-new, and the inhibitory activity of the Aphanamixoid A on breast cancer cells is unexpectedly strong.
Description
Technical field
The present invention relates to the new purposes of compd A phanamixoid A, relate in particular to the application of Aphanamixoid A in the preparation anti-breast cancer medicines.
Technical background
Cancer is to one of disease of human life's health hazard maximum, and annual have a large amount of people to die from cancer.The research and development of cancer therapy drug are the focuses of study of pharmacy always.Having 74% to be the natural product or derivatives thereof in the antitumor drug, is exactly the present reasonable antitumor drug of effect clinically such as paclitaxel and derivant thereof.Therefore, searching anticancer compound or lead compound have great importance from natural product.
The compd A phanamixoid A that the present invention relates to is one and delivered (Cai in 2012, J. Y. et al., 2012. Aphanamixoid A, a Potent Defensive Limonoid, with a New Carbon Skeleton from Aphanamixis polystachya. Organic Letters 14 (10), 2524 – 2527.) New skeleton compound, this chemical compound has brand-new framework types, present purposes only relates to insect antifeedant activity (Cai, J. Y. et al., 2012. Aphanamixoid A, a Potent Defensive Limonoid, with a New Carbon Skeleton from Aphanamixis polystachya. Organic Letters 14 (10), 2524 – 2527.), belong to open first for the purposes of the Aphanamixoid A that the present invention relates in preparation treatment breast cancer medicines, because framework types belongs to brand-new framework types, and its inhibition for breast cancer cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously breast carcinoma obviously has significant progress.
Summary of the invention
The invention provides the application of compd A phanamixoid A in the preparation antitumor drug.
The present invention adopts following technical scheme: the application of Aphanamixoid A in the preparation anti-breast cancer medicines, and the structural formula of Aphanamixoid A is shown in formula I:
The present invention finds that by external MTT anti-tumor activity evaluation Aphanamixoid A also has significant inhibitory action to the growth of human breast cancer cell strain 4T1, MCF-7, MDA-MB-231 and MCF-7B, suppresses the IC of this 4 strain Growth of Cells
50Value is respectively 0.12 ± 0.09 μ M, 0.35 ± 0.06 μ M, 0.23 ± 0.05 μ M and 0.19 ± 0.06 μ M.Therefore, Aphanamixoid A can for the preparation of anti-breast cancer medicines, have good development prospect.
The purposes of the Aphanamixoid A that the present invention relates in preparation treatment breast cancer medicines belongs to open first, because framework types belongs to brand-new framework types, and its inhibition for breast cancer cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously breast carcinoma obviously has significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
The specific embodiment
The preparation method of compd A phanamixoid A involved in the present invention is referring to document (Cai, J. Y. et al., 2012. Aphanamixoid A, a Potent Defensive Limonoid, with a New Carbon Skeleton from Aphanamixis polystachya. Organic Letters 14 (10), 2524 – 2527.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
Embodiment 1: the preparation of compd A phanamixoid A tablet involved in the present invention:
Get 20 and digest compound Aphanamixoid A, add conventional adjuvant 180 grams of preparation tablet, mixing, conventional tablet machine are made 1000.
Embodiment 2: the preparation of compd A phanamixoid A capsule involved in the present invention:
Get 20 and digest compound Aphanamixoid A, add conventional adjuvant such as starch 180 grams of preparation capsule, mixing is encapsulatedly made 1000.
Further specify its pharmaceutically active below by pharmacodynamic experiment.
Experimental example: adopt mtt assay assessing compound Aphanamixoid A to the growth inhibited effect of human breast cancer cell strain
1. method: the cell that is in the growth logarithmic (log) phase: human breast cancer cell strain 4T1, MCF-7, MDA-MB-231 and MCF-7B(buy from Chinese Academy of Sciences's cell bank) with 1.5 * 10
4The concentration kind is in 96 orifice plates.Suck original culture medium after cell culture 24 h are adherent.Test is divided into blank group, drug treating group.Blank group is changed 1640 culture medium that contain 10% hyclone; It is 100 μ M that the replacing of drug treating group contains concentration, 50 μ M, 10 μ M, 1 μ M, 0.1 μ M, the culture medium of the Aphanamixoid A of 0.01 μ M and 0.001 μ M.After cultivating 48 h, add the MTT of concentration 5 mg/mL, continue to be put in CO
2Incubator is cultivated 4 h, then suck 100 μ L supernatants along culture fluid top, add 100 μ L DMSO, 10 min are placed in the dark place, utilize microplate reader (Sunrise company product) to measure light absorption value (wavelength 570nm), and according to light absorption value calculating cell survival situation, 6 repeating holes are established in each processing.Cell survival rate (%)=Δ OD
Drug treating/ Δ OD
Blank* 100.
2. result: Aphanamixoid A has significant inhibitory action to the growth of human breast cancer cell strain 4T1, MCF-7, MDA-MB-231 and MCF-7B.This chemical compound suppresses the IC of human breast cancer cell strain 4T1, MCF-7, MDA-MB-231 and MCF-7B growth
50Value is respectively: 0.12 ± 0.09 μ M, 0.35 ± 0.06 μ M, 0.23 ± 0.05 μ M and 0.19 ± 0.06 μ M.
Shown that by above-described embodiment Aphanamixoid A of the present invention has good inhibitory action to the growth of human breast cancer cell strain 4T1, MCF-7, MDA-MB-231 and MCF-7B.Prove that thus Aphanamixoid A of the present invention has the anti-breast cancer activity, can be for the preparation of anti-breast cancer medicines.
Claims (1)
1.Aphanamixoid the application of A in the treatment breast cancer medicines, described compd A phanamixoid A structure is shown in formula I:
Formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210414597.5A CN102895224A (en) | 2012-10-25 | 2012-10-25 | Application of Aphanamixoid A in drugs for treating breast cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210414597.5A CN102895224A (en) | 2012-10-25 | 2012-10-25 | Application of Aphanamixoid A in drugs for treating breast cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102895224A true CN102895224A (en) | 2013-01-30 |
Family
ID=47567912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210414597.5A Pending CN102895224A (en) | 2012-10-25 | 2012-10-25 | Application of Aphanamixoid A in drugs for treating breast cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102895224A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105663121A (en) * | 2016-02-02 | 2016-06-15 | 南京正亮医药科技有限公司 | Application of Aogacillin B in preparation of breast cancer treatment drug |
-
2012
- 2012-10-25 CN CN201210414597.5A patent/CN102895224A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105663121A (en) * | 2016-02-02 | 2016-06-15 | 南京正亮医药科技有限公司 | Application of Aogacillin B in preparation of breast cancer treatment drug |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102895224A (en) | Application of Aphanamixoid A in drugs for treating breast cancer | |
| CN102872110B (en) | Application of Houttuynoid D in medicament for treating breast cancer | |
| CN102885806B (en) | Application of Aphanamixoid A in preparation of drug for treating laryngeal cancers | |
| CN102872010B (en) | Application of Aphanamixoid A in drugs for treating ovarian cancer | |
| CN102872075A (en) | Application of Houttuynoid E in drugs for treating breast cancer | |
| CN102885809A (en) | Application of Aphanamixoid A in medicament for treating pancreatic cancer | |
| CN103127091A (en) | Application of Aphanamixoid A in medicines curing colorectal cancer | |
| CN102872085B (en) | Application of Houttuynoid A in medicines for treating breast cancer | |
| CN102872121B (en) | Application of Houttuynoid C in medicament for treating laryngocarcinoma | |
| CN103120678A (en) | Application of Aphanamixoid A in medicine for treating liver cancer | |
| CN102872137B (en) | Application of Houttuynoid B in drug for treating cervical cancer | |
| CN103405418A (en) | Application of Chukrasone B in medicine for treating breast cancer | |
| CN102872125B (en) | Application of Houttuynoid C in medicament for treating cervical cancer | |
| CN102872086A (en) | Application of Houttuynoid A in medicines for treating skin cancer | |
| CN102872089A (en) | Application of Houttuynoid E in medicines for treating skin cancer | |
| CN103127080A (en) | Application of Aphanamixoid A in medicines curing skin cancer | |
| CN103120682A (en) | Application of Aphanamixoid A in medicine for treating bladder cancer | |
| CN103120680A (en) | Application of Aphanamixoid A in medicine for treating nasopharyngeal carcinoma | |
| CN103120666A (en) | Application of Aphanamixoid A in medicine for treating human cervical carcinoma | |
| CN103120679A (en) | Application of Aphanamixoid A in medicine for treating tongue cancer | |
| CN103462969A (en) | Application of Incarviatone A in medicaments for treating breast cancer | |
| CN103127090A (en) | Application of Aphanamixoid A in medicines curing kidney cancer | |
| CN102872102A (en) | Application of Houttuynoid C in medicine for treating breast cancer | |
| CN103356553A (en) | Application of Sarcaboside A in preparation of drug for treating breast cancer | |
| CN103479630A (en) | Application of Lycojaponicumin A in preparation of drugs for treating breast cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130130 |